Empagliflozin - Heart failure
You are here : Home > Formulary Search > Empagliflozin - Heart failure
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Blue
Formulations :
- Tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Documentation
PAD Profile
ChemicalSubstance :
Empagliflozin
Indication :
Heart failure
Group Name :
Keywords :
SGLT2s, SGLT2 inhibitors, sodium glucose co-transporter 2 inhibitors, chronic heart failure, CHF, HFrEF, reduced ejection fraction
Brand Names Include :
Jardiance
Important Information :
Dapagliflozin is the preferred SGLT-2 for heart failure.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3
Committee Recommendations (2)
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed that dapagliflozin will be the preferred SGLT-2 inhibitor in type 2 diabetes, Chronic Kidney Disease and Heart Failure.
The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.
Other Indications
Below are listed other indications that Empagliflozin is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Heart failure.
- Acetazolamide
- Bisoprolol fumarate
- Candesartan cilexetil
- Captopril
- Carvedilol
- Co-amilozide (Amiloride hydrochloride/hydrochlorot
- Dapagliflozin
- Digoxin
- Enalapril maleate
- Enoximone
- Eplerenone
- Hydralazine hydrochloride
- Ivabradine
- Levosimendan
- Lisinopril
- Losartan potassium
- Metolazone
- Milrinone lactate
- Nebivolol
- Perindopril erbumine
- Potassium canrenoate
- Prazosin hydrochloride
- Ramipril
- Sacubitril/valsartan
- Spironolactone
- Valsartan